Personalised medicine for cancer: From drug development into clinical practice

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 9, 2005, Pages 1463-1476

  Jain, Kewal K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

Anticancer drugs; Cancer; Cancer classification; Cancer vaccines; Combination of diagnosis with therapy; Molecular diagnostics; Personalised therapy; Pharmacogenetics; Pharmacogenomics; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BIOLOGICAL MARKER; BORTEZOMIB; BRCA1 PROTEIN; BRCA2 PROTEIN; CANCER VACCINE; CYCLIN DEPENDENT KINASE 2; DMAG 17; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUORODEOXYGLUCOSE; GEFITINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IBRITUMOMAB TIUXETAN; LIPOCORTIN 5; MONOCLONAL ANTIBODY; MUCIN 1; MULTIDRUG RESISTANCE PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN INHIBITOR; PROTEIN KINASE ZAP 70; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; PROTEIN RET; RETINOBLASTOMA PROTEIN; RNA; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALTERNATIVE RNA SPLICING; BREAST CANCER; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL ASSAY; CHROMOSOME ABERRATION; CLINICAL PRACTICE; CLINICAL TRIAL; COLON CANCER; COLON POLYPOSIS; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DNA MICROARRAY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; EARLY DIAGNOSIS; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; HUMAN; INDIVIDUALIZATION; LIFESTYLE; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MELANOMA; METASTASIS POTENTIAL; MICROSATELLITE INSTABILITY; MYELOMA; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOSOME; OVARY CANCER; PATIENT CARE; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOGENOMICS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRESCRIPTION; PROGNOSIS; PROSTATE CANCER; PROTEIN ELECTROPHORESIS; PROTEOMICS; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RNA INTERFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BIOPSY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CASE MANAGEMENT; CLINICAL TRIALS; COMPUTATIONAL BIOLOGY; CYTOCHROME P-450 CYP1A2; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRACTICE GUIDELINES;

EID: 23644448453     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.9.1463     Document Type: Review

References (53)

1. JAIN KK: Personalised medicine. Curr. Opin. Mol. Ther. (2002) 4:548-558.
2. JAIN KK: Personalised Medicine: Scientific and Commercial Aspects. Jain PharmaBiotech Publications, Basel (2005):1-442.
3. MICHIELS S, KOSCIELNY S, HILL C: Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet (2005) 365:488-492.
4. DYRSKJOT L, THYKJAER T, KRUHOFFER M et al.: Identifying distinct classes of bladder carcinoma using microarrays. Nat. Rev. Genet. (2002) 33:90-96.
5. DRESSMAN MA, BARAS A, MALINOWSKI R et al.: Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res. (2003) 63:2194-2199.
6. CLARKE PA, TE POELE R, WORKMAN P: Gene expression microarray technologies in the development of new therapeutic agents. Eur. J. Cancer (2004) 40:2560-2591.
7. BRACCO L, KEARSEY J: The relevance of alternative RNA splicing to pharmacogenomics. Trends Biotechnol. (2003) 21:346-353.
8. BRINKMAN BM: Splice variants as cancer biomarkers. Clin. Biochem. (2004) 37:584-594.
9. KOLE R, VACEK M, WILLIAMS T: Modification of alternative splicing by antisense therapeutics. Oligonucleotides (2004) 14:65-74.
10. MYERS CL, DUNHAM MJ, KUNG SY, TROYANSKAYA OG: Accurate detection of aneuploidies in array CGH and gene expression microarray data. Bioinformatics (2004) 20:3533-3543.
11. CHAN-HUI PY, STEPHENS K, WARNOCK RA, SINGH S: Applications of eTag trade mark assay platform to systems biology approaches in molecular oncology and toxicology studies. Clin. Immunol. (2004) 111:162-174.
12. MUNDLE SD, SOKOLOVA I: Clinical implications of advanced molecular cytogenetics in cancer. Expert Rev. Mol. Diagn. (2004) 4:71-81.
13. CARR KM, ROSENBLATT K, PETRICOIN EF, LIOTTA LA: Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum. Genomics (2004) 1:134-140.
14. JAIN KK: Applications of biochips: from diagnostics to personalized medicine. Curr. Opin. Drug Dis. Dev. (2004) 7:285-289.
15. WORKMAN P: The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemother. Pharmacol. (2003) 52(Suppl. 1):45-56.
16. JEZ JM, CHEN JC, RASTELLI G et al.: Crystal Structure and Molecular Modeling of 17-DMAG in Complex with Human Hsp90. Chem. Biol. (2003) 10:361-368.
17. STAUDT JM: Molecular diagnosis of the hematologic cancers. N. Engl. J. Med. (2003) 348:1777-1785.
18. WIESTNER A, ROSENWALD A, BARRY TS et al.: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood (2003) 101:4944-4951.
19. LAPOINTE J, LI C, HIGGINS JP et al.: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. USA (2004) 101:811-816.
20. SULLIVAN DC: Challenges and opportunities for in vivo imaging in oncology. Technol. Cancer Res. Treat. (2002) 1:419-422.
21. WEBER WA, PETERSEN V, SCHMIDT B et al.: Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J. Clin. Oncol. (2003) 21:2651-2657.
22. ANTOCH G, KANJA J, BAUER S et al.: Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J. Nucl. Med. (2004) 45:357-365.
23. MANDL SJ, MARI C, EDINGER M et al.: Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol. Imaging (2004) 3:1-8.
24. CRISTOFANILLI M, HAYES DF, BUDD GT et al.: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. (2005) 23:1420-1430.
25. PALUMBO KS, WANDS JR, SAFRAN H et al.: Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas (2002) 25:39-44.
26. LOO C, LOWERY A, HALAS N et al.: Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. (2005) 5:709-711.
27. HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (2003) 21:4342-4349.
28. HOLDENRIEDER S, STIEBER P, BODENMULLER H et al.: Circulating nucleosomes in serum. Ann. NY Acad. Sci. (2001) 945:93-102.
29. HOLDENRIEDER S, STIEBER P, VON PAWEL J et al.: Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin. Cancer Res. (2004) 10:5981-5987.
30. VOLLMER RT, GOVINDAN R, GRAZIANO SL et al.: Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin. Cancer Res. (2003) 9:1728-1733.
31. RIBIC CM, SARGENT DJ, MOORE MJ et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. (2003) 349:247-257.
32. EISENHAUER EA: From the molecule to the clinic-inhibiting HER2 to treat breast cancer. N. Engl. J. Med. (2001) 344:841-842.
33. KAO CH, HSIEH JF, TSAI SC et al.: Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. Clin. Cancer Res. (2000) 6:820-824.
34. ADAMS J, KAUFFMAN M: Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest. (2004) 22:304-311.
35. JAMIESON TA, BRIZEL DM, KILLIAN JK et al.: M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis. BMC Cancer (2003) 3:4.
36. ST CROIX B, RAGO C, VELCULESCU V et al.: Genes expressed in human tumor endothelium. Science (2000) 289:1197-1202.
37. DOLMA S, LESSNICK SL, HAHN WC et al.: Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell (2003) 3:285-296.
38. BALCH C, MONTGOMERY JS, PAIK HI et al.: New anti-cancer strategies: epigenetic therapies and biomarkers. Front. Biosci. (2005) 10:1897-1931.
39. ESTELLER M: DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. (2005) 17:55-60.
40. JAIN KK: Role of oncoproteomics in the personalized management of cancer. Expert Rev. Proteomics (2004) 1:49-55.
41. LU Y, WANG H, MILLS GB: Targeting PI3K-AKT pathway for cancer therapy. Rev. Clin. Exp. Hematol. (2003) 7:205-28.
42. LI J, WONG L: Identifying good diagnostic gene groups from gene expression profiles using the concept of emerging patterns. Bioinformatics (2002) 18:725-734.
43. FLUITER K, HOUSMAN D, TEN ASBROEK AL, BAAS F: Killing cancer by targeting genes that cancer cells have lost: allele-specific inhibition, a novel approach to the treatment of genetic disorders. Cell Mol. Life Sci. (2003) 60:834-843.
44. WEINSCHENK T, GOUTTEFANGEAS C, SCHIRLE M et al.: Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. (2002) 62:5818-5827.
45. WATTERS JW, KRAJA A, MEUCCI MA et al. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl. Acad. Sci. USA (2004) 101:11809-11814.
46. NAGASUBRAMANIAN R, INNOCENTI F, RATAIN MJ: Pharmacogenetics in cancer treatment. Ann. Rev. Med. (2003) 54:437-452.
47. BARRATT PL, SEYMOUR MT, STENNING SP et al.: DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet (2002) 360:1381-1391.
48. MACLEOD SL, NOWELL S, MASSENGILL J et al.: Cancer therapy and polymorphisms of cytochromes P450. Clin. Chem. Lab. Med. (2000) 38:883-887.
49. KRYNETSKI E, EVANS WE: Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene (2003) 22:7403-7413.
50. GARDNER SN, FERNANDES M: New tools for cancer chemotherapy: computational assistance for tailoring treatments. Mol. Cancer Ther. (2003) 2:1079-1084.
51. CUPERLOVIC-CULF M, BELACEL N, OUELETTE R: Determination of tumour marker genes from gene expression data. Drug Discov. Today (2005) 10:429-437.
52. WADLOW R, RAMASWAMY S. DNA microarrays in clinical cancer research. Curr. Mol. Med. (2005) 5:111-120.
53. GARDNER SN, FERNANDES M: Cytostatic anticancer drug development. J. Exp. Ther. Oncol. (2004) 4:9-18.